title: Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction.
abstract: Cell-based therapy is a promising therapy for myocardial infarction. Endogenous repair of the heart muscle after myocardial infarction is a challenge because adult cardiomyocytes have a limited capacity to proliferate and replace damaged cells. Pre-clinical and clinical evidence has shown that cell based therapy may promote revascularization and replacement of damaged myocytes after myocardial infarction. Adult stem cells can be harvested from different sources including bone marrow, skeletal myoblast, and human umbilical cord blood cells. The use of these cells for the repair of myocardial infarction presents various advantages over other sources of stem cells. Among these are easy harvesting, unlimited differentiation capability, and robust angiogenic potential. In this review, we discuss the milestone findings and the most recent evidence demonstrating the therapeutic efficacy and safety of the transplantation of human umbilical cord blood cells as a stand-alone therapy or in combination with gene therapy, highlighting the importance of optimizing the timing, dose and delivery methods, and a better understanding of the mechanisms of action that will guide the clinical entry of this innovative treatment for ischemic disorders, specifically myocardial infarction.
authors.affiliation: Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
authors.forename: Sandra A
authors.initials: SA
authors.lastname: Acosta
authors.forename: Nick
authors.initials: N
authors.lastname: Franzese
authors.forename: Meaghan
authors.initials: M
authors.lastname: Staples
authors.forename: Nathan L
authors.initials: NL
authors.lastname: Weinbren
authors.forename: Monica
authors.initials: M
authors.lastname: Babilonia
authors.forename: Jason
authors.initials: J
authors.lastname: Patel
authors.forename: Neil
authors.initials: N
authors.lastname: Merchant
authors.forename: Alejandra Jacotte
authors.initials: AJ
authors.lastname: Simancas
authors.forename: Adam
authors.initials: A
authors.lastname: Slakter
authors.forename: Mathew
authors.initials: M
authors.lastname: Caputo
authors.forename: Milan
authors.initials: M
authors.lastname: Patel
authors.forename: Giorgio
authors.initials: G
authors.lastname: Franyuti
authors.forename: Max H
authors.initials: MH
authors.lastname: Franzblau
authors.forename: Lyanne
authors.initials: L
authors.lastname: Suarez
authors.forename: Chiara
authors.initials: C
authors.lastname: Gonzales-Portillo
authors.forename: Theo
authors.initials: T
authors.lastname: Diamandis
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Shinozuka
authors.forename: Naoki
authors.initials: N
authors.lastname: Tajiri
authors.forename: Paul R
authors.initials: PR
authors.lastname: Sanberg
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kaneko
authors.forename: Leslie W
authors.initials: LW
authors.lastname: Miller
authors.forename: Cesar V
authors.initials: CV
authors.lastname: Borlongan
keywords: Angiogenesis; Cardiomyocytes; Gene therapy; Myocardial infarction; Umbilical cord blood